Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Avet-Loiseau, Hervé
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. [electronic resource] - Blood 09 2016 - 1174-80 p. digital
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
1528-0020
10.1182/blood-2016-03-707596 doi
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Dexamethasone--administration & dosage
Disease-Free Survival
Female
Humans
Lenalidomide
Male
Middle Aged
Multiple Myeloma--drug therapy
Oligopeptides--administration & dosage
Recurrence
Risk Factors
Survival Rate
Thalidomide--administration & dosage
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. [electronic resource] - Blood 09 2016 - 1174-80 p. digital
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
1528-0020
10.1182/blood-2016-03-707596 doi
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Dexamethasone--administration & dosage
Disease-Free Survival
Female
Humans
Lenalidomide
Male
Middle Aged
Multiple Myeloma--drug therapy
Oligopeptides--administration & dosage
Recurrence
Risk Factors
Survival Rate
Thalidomide--administration & dosage